Evidence map›Paper›PMID 36378052›Full record

ArticleJournal of traditional Chinese medicine = Chung i tsa chih ying wen pan2022

Effect of Dangfei Liganning capsule on liver X receptor α/steroid regulatory element binding protein-1/fatty acid synthase signal pathway in rats with metabolic- associated fatty liver disease.

L I Xiaoling, Sun Fengxia, Shang Zimeng, Zhang Yingxue, L I Jie, Zhang Qiuxiang

Open access · greenAbstract read
In one paragraph

Article in Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

L I XiaolingInfections Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.
Sun FengxiaInfections Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.
Shang ZimengInfections Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.
Zhang YingxueInfections Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.
L I JieInfections Department, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.
Zhang QiuxiangInfections Department, Beijing Hospital of Traditional Chinese Medicine Shunyi Branch, Beijing 101300, China.
Beijing Hospital of Traditional Chinese Medicine · CNShunyi Hospital of Beijing Traditional Chinese Medicine Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study the mechanism of Dangfei Liganning capsule in the treatment of rats with metabolic associated fatty liver disease (MAFLD).

methodsTotally 48 specific pathogen free Sprague-Dawley male rats were randomly divided into normal Group, model group, Dangfei Liganning high, moderate, and low-dose groups and Essentiale group which were fed with high fat diet for 8 weeks, and gavage and molding were carried out simultaneously. Dangfei Liganning high, middle and low-dose group were given 0.27, 0.135 and 0.0675 g·kg·d respectively by gavage, Essentiale group was given 0.123 g·kg·d by gavage, the same amount of distilled water was given by gavage in the normal group and the model group. The rats were weighed at the 0th week, 2nd week, 4th week, 6th week and 8th weekend respectively. The rats were sacrificed at the end of the 8th week. Serum levels of alanine aminotransferase (ALT), alanine aminotransferase (AST), triglyceride (TG), total cholesterol (CHO), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL-C), total protein (TP), albumin (Alb), globulin (GLB), total bilirubin (TBIL), direct bilirubin (DBIL), tumor necrosis factor-α(TNF-α) and interleukin-6 (IL-6) were measured. The levels of liver tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and liver pathology [hematoxylin and eosin (HE) staining, oil red O staining] were detected. The expression levels of liver X receptor α (LXRα), steroid regulatory element binding protein-1 (SREBP-1) and fatty acid synthase (FAS) were detected by immunohistochemistry, Western blot and reverse transcription-polymerase chain reaction reverse transcription-polymerase chain reaction.

resultsFrom the beginning to the 8th week, the growth rate of body weight in the Dangfei Liganning high-dose group was slower than all other groups. There was no significant difference in ALB level in all groups ( 0.05). Compared with the model group, the levels of ALT, AST, LDL-C, TG, CHO, TP, GLB, TBIL, DBIL, IL-6, TNF-α were significantly decreased and HDL-C were significantly increased in Dangfei Liganning high-dose group (0.01, < 0.05). HE and oil red O staining showed that the fatty lesions in rat liver were alleviated, while the expressions of LXRα, SREBP-1, FAS mRNA and protein were significantly decreased (0.01).

conclusionsDangfei Liganning capsule can slow down the increase of body weight of MAFLD rats, reduce the levels of transaminase, Lipid and inflammatory factors in MAFLD rats, promote the synthesis of liver protein and bile metabolism, and improve the liver fatty lesion of MAFLD rats, among which the Dangfei Liganning high-dose group is more effective. The mechanism of action may be through blocking LXR-SREBP-1-FAS signal pathway.

Indexed as

Non-alcoholic Fatty Liver DiseaseAlanine TransaminaseAnimalsAzo CompoundsBilirubinBody WeightCholesterol, LDLFatty Acid SynthasesInterleukin-6LiverLiver X ReceptorsMaleRatsRats, Sprague-DawleySignal TransductionSterol Regulatory Element Binding Protein 1Alanine TransaminaseAzo CompoundsBilirubinCholesterol, LDLFatty Acid SynthasesInterleukin-6Liver X Receptorsoil red OSterol Regulatory Element Binding Protein 1Tumor Necrosis Factor-alphaDangfei Liganning capsule.fatty acid synthasesliver X receptorsmetabolic associated fatty liver diseasesignal transductionsteroid regulatory element binding protein-1

Identifiers

PMID36378052
PMCPMC9924676
OpenAlexW4309362851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.